

INTERNATIONAL STANDARD

ISO
20776-1

First edition
2006-11-15

Clinical laboratory testing and *in vitro* diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices —

Part 1:

Reference method for testing the *in vitro* activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases

*Systèmes d'essais en laboratoire et de diagnostic in vitro — Essais de
réceptivité d'agents infectieux et évaluation des performances des
dispositifs de réceptivité antimicrobienne —*

*Partie 1: Méthode de référence pour la détermination de la sensibilité in
vitro aux agents microbiens des bactéries aérobies à croissance rapide
impliquées dans les maladies infectieuses*



Reference number
ISO 20776-1:2006(E)

© ISO 2006

PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

© ISO 2006

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword	iv
Introduction	v
1 Scope	1
2 Terms and definitions	1
3 Test procedures	4
3.1 General	4
3.2 Medium	4
3.3 Antimicrobial agents	4
3.4 Preparation of inoculum	9
3.5 Inoculation of microdilution trays	10
3.6 Incubation of microdilution trays	10
3.7 Reading results	10
3.8 Special test situations where the MIC result might give unreliable results	10
4 Quality control	11
Annex A (normative) Requirements for Mueller-Hinton broth	16
Bibliography	18

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 20776-1 was prepared by the European Committee for Standardization (CEN) Technical Committee CEN/TC 140, *In vitro diagnostic medical devices*, in collaboration with Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

ISO 20776 consists of the following parts, under the general title *Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices*:

- *Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases*
- *Part 2: Evaluation of performance of antimicrobial susceptibility test devices*

Introduction

In vitro susceptibility tests are performed on microorganisms suspected of causing disease, particularly if the organism is thought to belong to a species that may exhibit resistance to frequently used antimicrobial agents. The tests are also important in resistance surveillance, epidemiological studies of susceptibility and in comparisons of new and existing agents.

Dilution procedures are used to determine the minimum inhibitory concentrations (MICs) of antimicrobial agents and are the reference method for antimicrobial susceptibility testing. MIC methods are used in resistance surveillance, comparative testing of new agents, to establish the susceptibility of organisms that give equivocal results in routine tests, for tests on organisms where routine tests may be unreliable and when a quantitative result is required for clinical management. In dilution tests, microorganisms are tested for their ability to produce visible growth on a series of agar plates (agar dilution) or in broth (broth dilution) containing serial dilutions of the antimicrobial agent.

The lowest concentration of an antimicrobial agent (in mg/l) that, under defined *in vitro* conditions, prevents the appearance of visible growth of a microorganism within a defined period of time is known as the MIC. The MIC is a guide for the clinician to the susceptibility of the organism to the antimicrobial agent and aids treatment decisions. Careful control and standardisation is required for intra- and inter-laboratory reproducibility, as results may be significantly influenced by the method used. It is generally accepted that broth MIC tests are reproducible to within one doubling dilution of the real end point (i.e. \pm one well or tube in a doubling dilution series).

Broth dilution is a technique in which containers holding identical volumes of broth with antimicrobial agent solutions in incrementally (usually geometrically) increasing concentrations are inoculated with a known number of microorganisms.

Broth microdilution denotes the performance of the broth dilution test in microdilution trays.

The method described in this part of ISO 20776 is intended for the testing of pure cultures of aerobic bacteria that are easily grown by overnight incubation on agar and grow well in Mueller-Hinton broth, which may be supplemented. The broth microdilution method described in this part of ISO 20776 is essentially the same as those used in many countries, including France^[1], Germany^[2], Sweden^[3], the United Kingdom^[4], and the United States^[5]. The method is also essentially the same as the broth microdilution method published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST)^[6]. All these methods are based on those described by Ericsson and Sherris^[7].

Clinical laboratory testing and *in vitro* diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices —

Part 1:

Reference method for testing the *in vitro* activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases

WARNING — The use of this part of ISO 20776 may involve hazardous materials, operations and equipment. This part of ISO 20776 does not purport to address all of the safety problems associated with its use. It is the responsibility of the user of this part of ISO 20776 to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

1 Scope

This part of ISO 20776 describes one reference method, broth microdilution, for determination of MICs. The MIC reflects the activity of the drug under the described test conditions, and can be interpreted for clinical management purposes by taking into account other factors, such as drug pharmacology or bacterial resistance mechanisms. This allows categorization of bacteria as “susceptible” (S), “intermediate” (I), or “resistant” (R). In addition, MIC distributions can be used to define wild type or non-wild type bacterial populations. Although clinical interpretation of the MIC value is beyond the scope of this part of ISO 20776, modifications of the basic method are required for certain antimicrobial agent - bacteria combinations to facilitate clinical interpretation. These modifications are included in a separate table. It is advisable to compare other susceptibility testing methods (e.g. routine methods or diagnostic test devices) with this reference method for validation, in order to ensure comparable and reliable results.

2 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

2.1

antimicrobial agent

substance of biological, semi-synthetic or synthetic origin that inhibits the growth of or kills bacteria, and is thus of potential use in the treatment of infections

NOTE Disinfectants, antiseptics and preservatives are not included in this definition.

2.2 Antimicrobial agents — properties

2.2.1

potency

antimicrobially active fraction of a test substance, determined in a bioassay against a reference powder of the same substance

ISO 20776-1:2006(E)

NOTE The potency is expressed as mass fraction in milligrams per gram (mg/g), or as activity content in International Units (IU) per gram, or as a volume fraction or mass fraction in percent, or as an amount-of-substance concentration (mass fraction) in mole per litre of ingredients in the test substance.

2.2.2**concentration**

amount of an antimicrobial agent in a defined volume of liquid

NOTE 1 The concentration is expressed as mg/l.

NOTE 2 mg/l \equiv μ g/ml but it is not recommended to use the unit μ g/ml.

2.3**stock solution**

initial solution used for further dilutions

2.4**minimum inhibitory concentration****MIC**

lowest concentration that, under defined *in vitro* conditions, prevents visible growth of bacteria within a defined period of time

NOTE The MIC is expressed in mg/l.

2.5**breakpoint****BP**

specific values of parameters, such as MICs, on the basis of which bacteria can be assigned to the clinical categories "susceptible", "intermediate" and "resistant"

NOTE For current interpretive breakpoints, reference can be made to the latest publications of organizations employing this reference method (e.g. CLSI and EUCAST).

2.5.1**susceptible****S**

bacterial strain inhibited *in vitro* by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success

NOTE 1 Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic test system.

NOTE 2 This breakpoint can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).

2.5.2**intermediate****I**

bacterial strain inhibited *in vitro* by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect

NOTE 1 Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.

NOTE 2 This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.

NOTE 3 This class also indicates a "buffer zone", to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.

NOTE 4 These breakpoints can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).